Manufacturer
NOVARTIS PHARMA STEIN AG
Contents
Zoledronic Acid
Indication
Hypercalcaemia of malignancy, Bone metastases associated with solid tumours, Osteolytic lesions associated with multiple myeloma.
Instruction
Administer via IV infusion.
Drug interaction
Increased exposure of concomitant drugs eliminated by renal excretion (e.g. digoxin). Increased risk of hypocalcaemia w/ loop diuretics. Lowered serum Ca concentrations for prolonged periods w/ aminoglycosides. Increased risk of renal dysfunction w/ nephrotoxic agents.
Malaysia
